On CIRM taking credit for myelofibrosis work

There have been a few posts on californiastemcellreport on the issue of CIRM claiming credit for a research discovery that, perhaps, CIRM did not have much to do with. [For example,
CIRM Exaggerates Role in San Diego Clinical Trials Research, Scientist Says

IPBiz had an April 9 post on the science itself: Myelofibrosis, CIRM, and patents. In that context, one sees that the work from University of California, San Diego, by a team led by Catriona Jamieson (however much supported by CIRM) was part of a bigger research effort, that was not supported by CIRM at all.

Text on the californiastemcellreport indicates the Sikahema effect is at play: The CIRM statement, which is carried under the press release section of its web site, was modified following queries by the California Stem Cell Report. The release now says that a CIRM training grant was also involved. The current version of the news release, however, does not mention that it was altered from the original.

Californiastemcellreport (and Terri Somers) forgot to tell you a few things that you might want to know about.

For example, one might check out published US patent application 20070111238, inventors Jamieson; Catriona Helen M.; (Palo Alto, CA) ; Weissman; Irving L.; (Stanford, CA), with abstract -->

Methods, systems and kits are provided for the clinical staging of blood disorders including myelodysplastic syndrome, myeloproliferative diseases and leukemias by differential analysis of hematologic samples for the distribution of one or more hematopoietic stem or progenitor cell subsets. Additional functional, genetic, gene expression, proteomic or other molecular analyses of the hematopoietic stem and progenitor cells from the patients can also be employed in the staging methods of the invention.

One might also check out published US patent application 20070259904, assigned to TargeGen, inventors Noronha; Glenn et al.